RedHill Biopharma Ltd



Welcome to RedHill Biopharma Ltd.

RedHill Biopharma (NASDAQ: RDHL; TASE: RDHL) is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers.

.

The Company’s current product pipeline includes:

.

RHB-105 – A combination therapy for Helicobacter pylori infection, with a Phase III study underway.

 

RHB-104 – A combination therapy for the treatment of Crohn’s disease, with a phase III clinical study underway, and for multiple sclerosis, with a Phase IIa proof of concept study underway.

.

RHB-102 – A once-daily oral pill formulation of ondansetron, with a Phase III study in the U.S. for acute gastroenteritis and a planned European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting.

.

RHB-106 – An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.

.

MESUPRON® – A Phase II uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers.

 

RP101 –  A Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers, currently subject to an option-to-acquire by RedHill

 

RIZAPORT® (RHB-103) – An oral thin film formulation of rizatriptan, for the treatment of acute migraines, with a U.S. NDA under review by the FDA and a European marketing application submitted to the German BfArM in October 2014.

.

RHB-101 – A once-daily oral pill formulation of carvedilol, for the treatment of congestive heart failure and high blood pressure.

.

Upcoming Events & Presentations

For 2014 events and conferences, please visit the Investors section